Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …

Aromatase inhibition is considered a legitimate approach for the treatment of ER-positive
(ER+) breast cancer as it accounts for more than 70% of breast cancer cases. Aromatase …

Breast cancer is the most frequent female cancer and second cause of cancer-related
deaths among women around the world. Two thirds of breast cancer patients have hormone …

Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen
receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen …

Introduction: The occurrence of metal ions in biomolecules is required to exert vital cellular
functions. Metal-containing biomolecules can be modulated by small-molecule inhibitors …

Drug resistance is a major challenge in conventional endocrine therapy for estrogen
receptor (ER) positive breast cancer (BC). BC is a multifactorial disease, in which …

Abstract Cytochrome P450 (P450, CYP) 19A1 is the steroid aromatase, the enzyme
responsible for the 3‐step conversion of androgens (androstenedione or testosterone) to …

Ovarian granulosa cells (GCs) are the most important source of estrogen. Therefore,
aromatase (estrogen synthase), which is the key enzyme in estrogen synthesis, is not only …

Background: Estrogens are essential for the growth of breast cancer in the case of
premenopausal as well as in postmenopausal women. However, most of the breast cancer …

Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive
(ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For …